Given that 40–65% of MS patients experience cognitive impairments (188), PDE4 inhibition would not only reduce pathological hallmarks in the CNS of MS patients, but would also directly reduce a prominent MS-related symptom. The gene discussed is PDE4A; the disease is Cognitive impairment.